UPDATE 1-Bluebird prices gene therapy at 1.58 mln euros over 5 years
June 14, 2019 at 14:53 PM EDT
Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.58 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder. The company proposed an installment plan, with 315,000 euros paid up front and four additional annual payments due only if the treatment continues to be effective.
